Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland · Delayed Price · Currency is CHF 64.60
-1.00 (-1.52%)
Aug 21, 2026, 5:31 PM CET
Basilea Pharmaceutica AG Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 196.17 | 194.36 | 194.87 | 150.28 | 122.32 | 131.56 |
Other Revenue | 51.25 | 38.03 | 13.68 | 7.36 | 25.45 | 16.56 |
| 247.42 | 232.38 | 208.54 | 157.63 | 147.77 | 148.12 | |
Revenue Growth | 4.74% | 11.43% | 32.30% | 6.68% | -0.24% | 16.06% |
Cost of Revenue | 152.15 | 145.22 | 115.82 | 104.65 | 98.41 | 117.23 |
Gross Profit | 95.27 | 87.16 | 92.72 | 52.99 | 49.36 | 30.89 |
Selling, General & Admin | 35.4 | 34.91 | 31.02 | 31.08 | 28.55 | 27.89 |
Operating Expenses | 35.4 | 34.91 | 31.02 | 31.08 | 28.55 | 27.89 |
Operating Income | 59.88 | 52.25 | 61.7 | 21.91 | 20.81 | 3.01 |
Interest Expense | -2.84 | -3.36 | -4.34 | -11.2 | -9.85 | -8.15 |
Interest & Investment Income | 1.33 | 1.27 | 1.42 | 1.69 | 0.33 | 0.07 |
Other Non Operating Income (Expenses) | -0.09 | -4.29 | 1.49 | -1.94 | 0.81 | -1.24 |
EBT Excluding Unusual Items | 58.28 | 45.88 | 60.26 | 10.46 | 12.1 | -6.31 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.02 |
Other Unusual Items | 0.4 | - | - | - | - | -0.5 |
Pretax Income | 58.68 | 45.88 | 60.26 | 10.46 | 12.1 | -6.79 |
Income Tax Expense | 6.29 | 5.64 | -17.33 | 0.01 | -0.05 | 0.04 |
Net Income | 52.38 | 40.24 | 77.59 | 10.45 | 12.15 | -6.83 |
Net Income to Common | 52.38 | 40.24 | 77.59 | 10.45 | 12.15 | -6.83 |
Net Income Growth | -27.90% | -48.14% | 642.45% | -13.96% | - | - |
Shares Outstanding (Basic) | 12 | 12 | 12 | 12 | 12 | 12 |
Shares Outstanding (Diluted) | 14 | 14 | 14 | 12 | 12 | 12 |
Shares Change | -1.46% | -1.23% | 14.10% | 1.67% | 2.24% | 13.62% |
EPS (Basic) | 4.26 | 3.29 | 6.42 | 0.87 | 1.02 | -0.58 |
EPS (Diluted) | 4.01 | 3.14 | 5.82 | 0.86 | 1.02 | -0.58 |
EPS Growth | -26.73% | -46.05% | 577.28% | -15.69% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 55.3 | 59.47 | 72.65 | 13.43 | 3.92 | -32.6 |
Free Cash Flow Per Share | 4.05 | 4.35 | 5.24 | 1.11 | 0.33 | -2.79 |
Gross Margin | 38.51% | 37.51% | 44.46% | 33.62% | 33.40% | 20.86% |
Operating Margin | 24.20% | 22.48% | 29.59% | 13.90% | 14.09% | 2.03% |
Profit Margin | 21.17% | 17.32% | 37.21% | 6.63% | 8.22% | -4.61% |
Free Cash Flow Margin | 22.35% | 25.59% | 34.84% | 8.52% | 2.65% | -22.01% |
EBITDA | 60.92 | 54.06 | 63.43 | 23.19 | 21.71 | 3.56 |
EBITDA Margin | 24.62% | 23.27% | 30.42% | 14.71% | 14.69% | 2.40% |
D&A For EBITDA | 1.05 | 1.81 | 1.73 | 1.28 | 0.9 | 0.55 |
EBIT | 59.88 | 52.25 | 61.7 | 21.91 | 20.81 | 3.01 |
EBIT Margin | 24.20% | 22.48% | 29.59% | 13.90% | 14.09% | 2.03% |
Effective Tax Rate | 10.72% | 12.28% | - | 0.10% | - | - |
Revenue as Reported | 247.42 | 232.38 | 208.54 | 157.63 | 147.77 | 148.12 |